Template:Vasopressor table

Revisión del 07:22 18 feb 2015 de Rossdonaldson1 (discusión | contribs.) (Created page with "===Vasopressors=== {| class="wikitable" |- ! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! Arrhythmias !! Special Notes |- | Dobutamine || 2.5mcg/k...")
(difs.) ← Revisión anterior | Revisión actual (difs.) | Revisión siguiente → (difs.)

Vasopressors

Pressor Initial Dose Max Dose Cardiac Effect BP Effect Arrhythmias Special Notes
Dobutamine 2.5mcg/kg/min 10-40 mcg/kg/min mainly inotrope (ß1) alpha effect minimal Some HR(ß1) increase. Also Increase SA and AV node fx Debut Research 1979[1] Isoproterenol has most Β2 vasodilatory and Β1 HR effects
Dopamine 2mcg/kg/min 20-50 mcg/kg/min β1 and NorEpi release α effects if > 20mcg/kg/min Arrhythmogenic from β1 effects More adverse events when used in shock compared to Norepi[2]
Norepinephrine 8-12mcg/min 30 mcg/min β1 direct effect β1 and α1,2 effects Less arrhythmias than Dopamine[2] Increases MAP, coronary perfusion pressure, little β2 effects.
Milrinone 50mcg/kg x 10 min 0.375-75mcg/kg/min Direct influx of Ca2+ channels Smooth muscle vasodilator PDE Inhibitor which increases Ca2+ uptake by sarcolemma. No venodilatory activity
Phenylephrine 100-180mcg/min then 40-60mcg/min 0.4-9 mcg/kg/min Alpha agonist Long half life
Vasopressin Fixed Dose 0.4 U/min unknown increases via ADH peptide should not be titrated due to ischemic effects
  1. Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine
  2. 2.0 2.1 De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789